Quarterly Report (10-q)

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended June 30, 2019
or
¨	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from _____________ to _____________

 

Commission File Number: 333-207765

 

ACRO BIOMEDICAL CO., LTD.

(Exact name of registrant as specified in its charter)

    

Nevada		47-1950356
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)
12175 Visionary Way, Suite 1160; Fishers, Indiana 46038
(Address of principal executive offices)
[phone]
(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  ¨ Yes      x No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). x Yes     ¨ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a small reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	x	Smaller reporting company	x
		Emerging growth company	¨

 

If an emerging growth company, indicate by a check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): ¨ Yes     x No

 

Securities registered pursuant to Section 12(b) of the Exchange Act: None

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 47,760,000 shares of common stock on August 13, 2019.

 

ACRO BIOMEDICAL CO., LTD.

 

INDEX

 

			Page No.
Part I: Financial Information
Item 1:	Financial Statements		4
	Unaudited Balance Sheets as of June 30, 2019 and September 30, 2018		4
	Statements of Operations for the three and nine months ended June 30, 2019 and 2018 (Unaudited)		5
	Unaudited Statement of Changes in Stockholders’ Equity for the three and nine months ended June 30, 2019 and 2018.		6
	Statements of Cash Flows for the nine months ended June 30, 2019 and 2018 (Unaudited)		7
	Notes to Unaudited Financial Statements		8
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations		11
Item 3:	Quantitative and Qualitative Disclosures about Market Risk		13
Item 4:	Controls and Procedures		13
Part II: Other Information
Item 6:	Exhibits		14

 

2

Table of Contents

 

FORWARD-LOOKING STATEMENTS

 

This report contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements, but are not deemed to represent an all-inclusive means of identifying forward-looking statements as denoted in this report. Additionally, statements concerning future matters are forward-looking statements.

 

Although forward-looking statements in this report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under the headings “Risks Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our annual report on Form 10-K for the year ended September 30, 2018, in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Form 10-Q and information contained in other reports that we file with the SEC. You are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this report.

 

We file reports with the SEC. The SEC maintains a website (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.

 

We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this report, except as required by law. Readers are urged to carefully review and consider the various disclosures made throughout the entirety of this quarterly report, which are designed to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

 

3

Table of Contents

 

ITEM 1: FINANCIAL STATEMENTS

  ACRO BIOMEDICAL CO., LTD.

Balance Sheets

(Unaudited)

 

		June 30,				September 30,
		2019				2018
ASSETS
Current Assets
Cash		$	231			$	1,148
Inventories			1,060,000				1,146,600
Prepaid expenses			6,000				330,089
Security deposit			4,992				-
Total Current Assets			1,071,223				1,477,837
Security deposit			-				4,992
Deferred tax asset			9,871				-
TOTAL ASSETS		$	1,081,094			$	1,482,829
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Accounts payable and accrued expenses		$	9,690			$	7,312
Income tax payable			-				92,227
Deferred revenue			20,000				-
Due to related parties			103,401				141,136
Total Current Liabilities			133,091				240,675
TOTAL LIABILITIES			133,091				240,675
Stockholders’ Equity
Preferred stock: 25,000,000 authorized; $0.001 par value; no shares issued and outstanding			-				-
Common stock: 100,000,000 authorized; $0.001 par value; 47,760,000 and 47,760,000 shares issued and outstanding as of June 30, 2019 and September 30, 2018, respectively			47,760				47,760
Additional paid-in capital			870,414				868,975
Related earnings			29,829				325,419
Total Stockholders’ Equity			948,003				1,242,154
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		$	1,081,094			$	1,482,829

 

The accompanying notes are an integral part of these unaudited financial statements.

 

4

Table of Contents

 

ACRO BIOMEDICAL CO., LTD.

Statements of Operations

(Unaudited)

 

		Three Months Ended								Nine Months Ended
		June 30,								June 30,
		2019				2018				2019				2018
Revenues		$	-			$	2,199,000			$	1,354,000			$	5,608,000
Cost of revenues			-				1,959,100				1,218,600				5,027,200
Gross profit			-				239,900				135,400				580,800
Operating expenses
Selling, general and administrative			68,092				63,674				512,493				226,336
Total operating expenses			68,092				63,674				512,493				226,336
Other expense
Interest expense - related party			609				-				1,439				-
Total other expenses			609				-				1,439				-
Income (loss) before income tax provision (credit)			(68,701	)			176,226				(378,532	)			354,464
Income taxes provision (credit)			(17,877	)			59,917				(82,942	)			88,476
Net income (loss)		$	(50,824	)		$	116,309			$	(295,590	)		$	265,988
Basic and dilutive income (loss) per share of common stock		$	(0.00	)		$	0.00			$	(0.01	)		$	0.01
Weighted average number of shares of common stock outstanding			47,760,000				47,660,000				47,760,000				47,660,000

 

The accompanying notes are an integral part of these unaudited financial statements.

 

5

Table of Contents

 

ACRO BIOMEDICAL CO., LTD.

Statements of Changes in Stockholders’ Equity

(Unaudited)

 

										Additional				Retained earnings				Total
		Common Stock								Paid in				Accumulated				Stockholders’
		Shares				Amount				Capital				Deficit				Equity
Balance, September 30, 2018			47,760,000			$	47,760			$	868,975			$	325,419			$	1,242,154
Imputed interest on related party loans			-				-				722				-				722
Net loss			-				-				-				(75,016	)			(75,016	)
Balance, December 31, 2018			47,760,000				47,760				869,697				250,403				1,167,860
Imputed interest on related party loans			-				-				108				-				108
Net loss			-				-				-				(169,750	)			(169,750	)
Balance, March 31, 2019			47,760,000			$	47,760			$	869,805			$	80,653			$	998,218
Imputed interest on related party loans			-				-				609				-				609
Net loss			-				-				-				(50,824	)			(50,824	)
Balance, June 30, 2019			47,760,000			$	47,760			$	870,414			$	29,829			$	948,003

 

										Additional				Retained earnings				Total
		Common Stock								Paid in				Accumulated				Stockholders’
		Shares				Amount				Capital				Deficit				Equity (Deficit)
Balance, September 30, 2017			47,660,000			$	47,660			$	557,912			$	(94,241	)		$	511,331
Net income			-				-				-				80,227				80,227
Balance, December 31, 2017			47,660,000				47,660				557,912				(14,014	)			591,558
Net income			-				-				-				69,452				69,452
Balance, March 31, 2018			47,660,000			$	47,660			$	557,912			$	55,438			$	661,010
Net income			-				-				-				116,309				116,309
Balance, June 30, 2018			47,660,000			$	47,660			$	557,912			$	171,747			$	777,319

 

The accompanying notes are an integral part of these unaudited financial statements.

 

6

Table of Contents

 

ACRO BIOMEDICAL CO., LTD.

Statements of Cash Flows

(Unaudited)

 

		Nine Months Ended
		June 30,
		2019				2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)		$	(295,590	)		$	265,988
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Stock based compensation			300,089				-
Imputed interest - related parties			1,439				-
Deferred tax asset			(9,871	)			-
Adjustment of Income tax payable			(73,071	)			-
Changes in operating assets and liabilities:
Inventories and purchase deposit to vendor			86,600				(439,000	)
Prepaid expenses			24,000				(50,000	)
Security deposit			-				(4,992	)
Accounts payable and accrued expenses			2,378				3,276
Income tax payable			(19,156	)			88,476
Deferred revenue			20,000				-
Net cash provided by (used in) operating activities			36,818				(136,252	)
CASH FLOWS FROM FINANCING ACTIVITIES
Advances from related parties			103,601				104,057
Repayment to related parties			(141,336	)			-
Net cash provided by (used in) financing activities			(37,735	)			104,057
Net change in cash and cash equivalents			(917	)			(32,195	)
Cash and cash equivalent at beginning of period			1,148				36,810
Cash and cash equivalent at end of period		$	231			$	4,615
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for income taxes		$	19,156			$	-
Cash paid for interest		$	-			$	-

 

The accompanying notes are an integral part of these unaudited financial statements.

 

7

Table of Contents

 

ACRO BIOMEDICAL CO., LTD.

Notes to Financial Statements

June 30, 2019

(Unaudited)

 

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Acro Biomedical Co., Ltd. (the “Company”) is a Nevada corporation incorporated on September 24, 2014 under the name Killer Waves Hawaii, Inc., which was changed to Acro Biomedical Co., Ltd. on January 30, 2017. The Company’s current business is the purchase and sale of cordyceps related products and metallothionein MT-3 elizer, a protein that, in powder form, is used in health supplements. Cordyceps is a fungus that is used in traditional Chinese medicine. The Company intends to conduct research and development on its own proprietary products based on cordyceps sinensis, but, as of June 30, 2019, has not commenced such activities.

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Unaudited Interim Financial Statements

 

The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with Rule 8-03 of Regulation S-X. Accordingly, the unaudited interim financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended September 30, 2018 have been omitted; these unaudited interim financial statements should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended September 30, 2018 included within the Company’s annual report on Form 10-K.

 

In the opinion of management, all adjustments consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position; (b) the result of operations; and (c) cash flows, have been made in order to make the unaudited interim financial statements presented not misleading. The results of operations for such interim periods are not necessarily indicative of operations for a full year.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

 

Revenue Recognition

 

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

 

	·	identify the contract with a customer;
	·	identify the performance obligations in the contract;
	·	determine the transaction price;
	·	allocate the transaction price to performance obligations in the contract; and
	·	recognize revenue as the performance obligation is satisfied.

 

Under these criteria, the Company generally recognizes revenue when its products are delivered to customers in accordance with the written sales terms.

 

8

Table of Contents

 

Inventories

 

Inventories consist primarily of finished goods. Inventories are valued at the lower of cost or net realizable value. The Company determines cost on the basis of first-in, first-out methods. The Company periodically reviews inventories for obsolescence and any inventories identified as obsolete are written down or written off. Although the Company believes that the assumptions it uses to estimate inventory write-downs are reasonable, future changes in these assumptions could provide a significantly different result. No inventory markdown was recorded for the nine months ended June 30, 2019 and 2018.

 

Net Income (Loss) Per Share of Common Stock

 

The Company has adopted ASC Topic 260, “ Earnings per Share” which requires presentation of basic earnings per share on the face of the statements of operations for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic earnings per share computation. In the accompanying financial statements, basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock and potentially dilutive outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through contingent share arrangements, stock options and warrants unless the result would be antidilutive. There were no potentially dilutive shares of common stock outstanding for the nine months ended June 30, 2019 and 2018.

 

NOTE 3 – PREPAID EXPENSE

 

At June 30, 2019 and September 30, 2018, prepaid expenses totaled $6,000 and $330,089, respectively. Prepaid expenses at June 30, 2019 consisted of public-company related fees and at September 30, 2018 consisted primarily of professional fees, including compensation for consulting services that were paid through the issuance of common stock which fees which are being amortized over the life of the applicable agreements. As of June 30, 2019, the fees are fully amortized.

 

NOTE 4 - RELATED PARTY TRANSACTIONS

 

At June 30, 2019 and September 30, 2018, the Company owed $103,401 and $99,265 to a stockholder who is not a 5% stockholder for non-interest-bearing advances made to or on behalf of the Company, respectively. At September 30, 2018, the Company owed $41,871 to its chief executive officer. These advances are due on demand.

 

During the nine months ended June 30, 2019, (a) the Company repaid $41,871 to its chief executive officer, (b) the stockholder paid expenses of $83,601 on behalf of the Company, (c) the stockholder made a loan of $20,000 to the Company and (d) the Company repaid $99,465 to the stockholder.

 

The Company has imputed interest at the rate of 4% on the advances made to the Company in the amount of $1,439 during the nine months ended June 30, 2019.

 

NOTE 5 - COMMITMENTS AND CONTINGENCIES

 

On November 30, 2017, the Company entered into a lease agreement to rent storage space in Hong Kong for a two-year term at HK$19,500 (approximately $2,500) per month. The Company paid $4,992 (HK$39,000) as a security deposit. For the nine months ended June 30, 2019 and 2018, the Company incurred rent expense of $23,680 and $17,605, respectively

 

NOTE 6 – CONCENTRATION

 

Revenue

 

During the nine months ended June 30, 2019, all revenue was derived from sales contracts with two customers, which represent 94% and 6%, respectively, of total revenues. All such revenue was generated during the quarter ended December 31, 2018.

 

9

Table of Contents

 

During the nine months ended June 30, 2018, all revenue was derived from seven sales contracts with two customers which represent 67% and 33%, respectively, of total revenues.

 

Purchases

 

During the nine months ended June 30, 2019, all purchases were derived from purchase contracts with one supplier during the quarter ended December 31, 2018.

 

During the nine months ended June 30, 2018, all purchases were derived from purchase contracts with two suppliers which represent 58% and 42%, respectively, of total purchases.

 

NOTE 7 – INCOME TAX

 

During the nine months ended June 30, 2019, the Company paid income tax for fiscal year 2018 of $19,156.

 

The reconciliation of income tax expense at the U.S. statutory rate of 21%, to the Company’s effective tax rate is as follows:

 

		Nine Months Ended June 30,
		2019				2018
Income tax expense (benefit) at statutory rate		$	(79,492	)		$	120,518
Tax adjustment
Expense not deductible in current period			69,319				-
Imputed interest			302				-
Adjustment of prior year income tax			(73,071	)			-
Change of valuation allowance			-				(32,042	)
Income tax expense (benefit)		$	(82,942	)		$	88,476

 

Net deferred tax assets consist of the following components:

 

		June 30,				September 30,
		2019				2018
Operating loss carry forward		$	9,871			$	32,042
Operating losses utilized			-				(32,042	)
Deferred tax asset		$	9,871			$	-

 

As of June 30, 2019, the Company has approximately $47,000 net operating loss carryforwards available in the U.S. to reduce future taxable income which can be carryforward indefinitely. The Company determined that it is more likely than not that the deferred tax assets will be utilized in the future because the Company expects further earnings based on management s estimates. The Company recorded deferred tax assets of approximately $9,871 as of June 30, 2019.

 

NOTE 8 - SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events that have occurred after the date of the balance sheet through the date of issuance of these financial statements and determined that no subsequent event requires recognition or disclosure to the financial statements.

 

10

Table of Contents

 

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of financial condition and results of operations should be read in conjunction with our financial statements and related notes included elsewhere in this report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. See “Forward-Looking Statements.”

 

Overview

 

Since January 30, 2017, following a change of control, we have been engaged in the business of developing and marketing nutritional products that promote wellness and a healthy lifestyle. Our business to date has involved the purchase of products from two suppliers and the sale of these products to two unrelated customers. All of our sales to date have been sales of cordyceps related products and, commencing in the second quarter of the year ended September 30, 2018, metallothionein MT-3 elizer. Cordyceps is a fungus that is used in traditional Chinese medicine. Cordyceps sinensis has been described as a medicine in old Chinese medical books and Tibetan medicine. It is a rare combination of a caterpillar and a fungus and found at altitudes above 4500m in Sikkim. The encoded protein in metallothionein MT-3 is a growth inhibitory factor, and reduced levels of the protein are observed in the brains of individuals with some metal-linked neurodegenerative disorders such as Alzheimer’s disease. We may also seek to market other products which we see as complimentary to our present products. We intend to conduct research and development on our own proprietary products based on cordyceps sinensis, however, to date we have not commenced such activities and we cannot assure you that we will do so. We can give no assurance that we can or will be successful in developing marketable products or expanding our customer base or supply chain.

 

We did not generate any revenue since the quarter ended December 31, 2018, having generated no revenues during the three months ended June 30, 2019 (the “June 2019 quarter”) or the quarter ended March 31, 2019. All of our sales to date were made to two customers who sell our products in the People’s Republic of China. One of these customers accounted for 94% of our revenue in the nine months ended June 30, 2019 (the “June 2019 period”) and 67% for the nine months ended June 30, 2018 (the “June 2018 period”). Thus, we are dependent upon one major customer whose ability to sell our product is dependent upon the market for cordyceps related products and metallothionein MT-3 elizer products in China. We believe our failure to generate sales reflects a downturn in the market in the PRC for products such as ours, and we cannot assure you that the market will improve. We have received orders during the fourth quarter and we anticipate that we will generate revenue from these orders during the quarter. However, we cannot assure you as to whether we will generate any significant revenue or profitable operations during or after the quarter ending September 30, 2019.

 

At present, we have no full-time employees. We face significant risks in implementing our business plan including, but not limited to, our ability to raise the necessary financing either through the sale of debt or equity securities or through a loan facility, our ability to increase our customer base and supply chain, our ability to increase our gross margins, our ability to hire and retain qualified research and development, marketing and administrative personnel, our ability to develop products and to market in the United States and other western markets any products we may develop, our ability to comply with any government regulations relating to the manufacture, distribution and marketing any products we develop. We cannot assure you that we can or will develop any products or generate revenue or profits in the future.

 

Although we may to seek to raise funds in the equity market, we can give no assurance as to the availability or terms of any such financing. Our failure to generate revenues in the second and third quarters of the current fiscal year, and the absence of purchase orders is likely to make it more difficult for us to raise money in the equity market. There is no active trading market in our common stock, and any sale of our equity securities could result in material dilution to our stockholders. If we are not able to raise the necessary funds, we may be unable to continue in business.

 

11

Table of Contents

 

Results of Operations

 

For the three and nine months ended June 30, 2019 and 2018.

 

For the three months-ended June 30, 2019, we had no revenues, operating expenses of $68,092, which were mainly professional fees related to our status as a public company, loss before income taxes of $68,701, an income tax credit of $17,877, and a net loss of $50,824 or $(0.00) per share (basic and diluted).

 

For the three months ended June 30, 2018 (the “June 2018 quarter”), we generated revenue of $2,199,000, gross profit of $239,900, representing a gross margin of 10.9%, operating expenses of $63,674, income before income taxes of $176,226, income taxes of $59,917, and net income of $116,309, or $0.00 per share (basic and diluted).

 

For the nine months ended June 30, 2019 (the “June 2019 period”), we had revenues of $1,354,000, all of which were generated during the first quarter of the fiscal year, a gross profit of $135,400, representing a gross margin of 10.0%, operating expenses of $512,493, principally non-cash compensation of $300,089 and professional fees relating to our SEC filings, a loss before income taxes before income taxes of $378,532, an income tax credit of $82,942, and a net loss of $295,590, or $(0.01) per share (basic and diluted).

 

For the nine months ended June 30, 2018 (the “June 2018 period”), we had revenues of $5,608,000, a gross profit of $580,800, representing a gross margin of 10.3%, operating expenses of $226,336, principally professional fees relating to our SEC filings, income from operations of $354,464, income tax of $88,476, and net income of $265,988, or $0.01 per share (basic and diluted).

 

One customer accounted for 94% of our revenue for the June 2019 period and 67% of our revenue for the June 2018 period. A second customer accounted for 6% of our revenue for the June 2019 period and 33% of our revenue for the June 2018 period.

 

Because of our dependence on two customers, our revenue in any quarter is dependent upon both the timing of orders from this customer and the delivery of product from our supplier. Our loss for the June 2019 quarter and the June 2019 period also reflected the amortization of non-cash consulting fees paid to consultants. The consultants accepted stock as compensation in view of our lack of cash.

 

Liquidity and Capital Resources

 

The following table summarizes our changes in working capital from September 30, 2018 to June 30, 2019:

 

		June 30, 2019				September 30, 2018				Change				% Change
Current assets		$	1,071,223			$	1,477,837			$	(406,614	)			(27.5	)%
Current liabilities		$	133,091			$	240,675			$	(107,584	)			(44.7	)%
Working capital		$	938,132			$	1,237,162			$	(299,030	)			(24.2	)%

 

Our principal current asset is inventory, which was $1,060,000 at June 30, 2019 and $1,146,600 at September 30, 2018. To the extent that we are not able to sell our inventory, our working capital will be materially impaired.

 

The following table summarizes our cash flows for the nine months ended June 30, 2019 and 2018:

 

		Nine Months Ended June 30,
		2019				2018
Cash provided by (used in) operating activities		$	36,818			$	(136,252	)
Cash provided by (used in) financing activities			(37,735	)			104,057
Cash and cash equivalents end of period			231				4,615

 

Cash provided by operating activities of $36,818 for the June 2019 period reflected primarily our net loss of $295,590, increased primarily by stock-based compensation of $300,089, a decrease in inventory of $86,600, decrease in prepaid expenses of $24,000, an increase in deferred revenues of $9,871, and an adjustment in income tax payable of $73,071.

 

12

Table of Contents

 

Cash used by operating activities of $136,252 for the June 2018 period reflected primarily our net income of $265,988, reduced by an increase in inventories and purchase deposit to vendor of $439,000, an increase in prepaid expenses of $50,000 and an increase in income tax payable of $88,476.

 

We did not generate any cash from investing activities for the June 2019 period or the June 2018 period.

 

Our cash used in financing activities of $37,735 for the June 2019 period represented advances from related parties of $103,601 and repayments to related parties of $141,336. For the June 2018 period, our cash provided by financing activities represented advances from related parties of $104,057.

 

Critical Accounting Policy and Estimates

 

Our critical accounting policies are disclosed in Note 2 or Notes to Financial Statements.

 

Recent Accounting Pronouncements

 

Management has considered all recent accounting pronouncements. Our management believes that these recent pronouncements will not have a material effect on our financial statements.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

 

Item 3: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Smaller reporting companies are not required to provide the information required by this item.

 

Item 4: CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We conducted an evaluation of the effectiveness of our disclosure controls and procedures (“Disclosure Controls”), as defined by Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of June 30, 2019, the end of the period covered by this Quarterly Report on Form 10-Q. The Disclosure Controls evaluation was done under the supervision and with the participation of management, including our chief executive officer and chief financial officer, which positions are held by the same person who assumed such positions on January 30, 2017 and who is our only employee and who does not work for us on a full-time basis. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon this evaluation, our chief executive officer and chief financial officer, concluded that, due to the inadequacy of our internal controls over financial reporting, our sole employee being our chief executive and financial officer and our limited internal audit function, our disclosure controls were not effective as of June 30, 2019, such that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to the president and treasurer, as appropriate to allow timely decisions regarding disclosure.

 

Changes in Internal Control over Financial Reporting

 

As reported in our annual report on Form 10-K for the year ended September 30, 2018, management has determined that our internal controls contain material weaknesses due to the absence of segregation of duties, as well as lack of qualified accounting personnel and excessive reliance on third party consultants for accounting, financial reporting and related activities. The lack of any separation of duties, with the same person, who is our only employee who serves as both chief executive officer and chief financial officer, who is our sole director and who does not have an accounting background and serves on a part-time basis, makes it unlikely that we will be able to implement effective internal controls over financial reporting in the near future.

 

During the period ended June 30, 2019, there was no change in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

13

Table of Contents

 

PART II – OTHER INFORMATION

Item 6: EXHIBITS

 

Exhibits

 

Exhibit Number		Description of Exhibits
31.1		Section 302 Certificate of Chief Executive Officer and Principal Financial Officer.
32.1		Section 906 Certificate of Chief Executive Officer and Principal Financial Officer.
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Schema Document
101.CAL		XBRL Taxonomy Calculation Linkbase Document
101.DEF		XBRL Taxonomy Definition Linkbase Document
101.LAB		XBRL Taxonomy Label Linkbase Document
101.PRE		XBRL Taxonomy Presentation Linkbase Document

 

14

Table of Contents

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

	ACRO BIOMEDICAL CO., LTD.
Dated: August 14 , 2019	By:	/s/ Pao-Chi Chu
		Pao-Chi Chu
		Chief Executive Officer and Chief Financial Officer

 

15